Genprex (GNPX) Shares Outstanding (2016 - 2026)
Genprex (GNPX) posted quarterly Shares Outstanding (Entity) of $316000.0 for Q1 2026, up 2176.99% year-over-year from $13878.0 in Q1 2025, and up 645.34% quarter-over-quarter from $42397.0 in Q4 2025.
Genprex (GNPX) Shares Outstanding (2016 - 2026) Analysis & Trends
Genprex's Shares Outstanding (Entity) history runs 11 years deep, the most recent figure standing at $316000.0 for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2176.99% year-over-year to $316000.0; the TTM figure through Mar 2026 stood at $316000.0 (up 2176.99% YoY), while the FY2025 annual figure was $42397.0, up 1064.11% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $316000.0, up from $42397.0 in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $316000.0 in Q1 2026, with the low at $1088.0 in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $1748.0 (2024), against an average of $26602.8.
- The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Entity) gained 0.46% in 2022, then surged 2176.99% in 2026.
- Genprex's Shares Outstanding (Entity) stood at $1093.0 in 2022, then gained by 23.6% to $1351.0 in 2023, then soared by 169.58% to $3642.0 in 2024, then jumped by 1064.11% to $42397.0 in 2025, then soared by 645.34% to $316000.0 in 2026.
- Business Quant data shows GNPX's Shares Outstanding (Entity) at $316000.0 in Q1 2026, $42397.0 in Q4 2025, and $34568.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | 473,162.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 316,000.00 |
| Dec 31, 2025 | 42,397.00 |
| Sep 30, 2025 | 34,568.00 |
| Jun 30, 2025 | 25,085.00 |
| Mar 31, 2025 | 13,878.00 |
| Dec 31, 2024 | 3,642.00 |
| Sep 30, 2024 | 3,182.00 |
| Jun 30, 2024 | 1,965.00 |
| Mar 31, 2024 | 1,471.00 |
| Dec 31, 2023 | 1,243.00 |
| Sep 30, 2023 | 1,314.00 |
| Jun 30, 2023 | 1,181.00 |
| Mar 31, 2023 | 1,124.00 |
| Dec 31, 2022 | 1,090.00 |
| Sep 30, 2022 | 1,091.00 |
| Jun 30, 2022 | 1,088.00 |
| Mar 31, 2022 | 1,088.00 |
| Dec 31, 2021 | 1,070.00 |
| Sep 30, 2021 | 1,082.00 |
| Jun 30, 2021 | 1,077.00 |